StockNews.com initiated coverage on shares of Arch Biopartners (NYSE:ARCH – Free Report) in a report published on Saturday. The brokerage issued a hold rating on the stock.
Arch Biopartners Stock Performance
Arch Biopartners stock opened at $134.83 on Friday. Arch Biopartners has a 12-month low of $116.44 and a 12-month high of $180.65.
Institutional Investors Weigh In On Arch Biopartners
A hedge fund recently bought a new stake in Arch Biopartners stock. Total Clarity Wealth Management Inc. purchased a new stake in Arch Biopartners Inc. (NYSE:ARCH – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 329 shares of the company’s stock, valued at approximately $47,000.
See Also
- Five stocks we like better than Arch Biopartners
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
- What is the NASDAQ Stock Exchange?
- 4 Automaker Stocks React to Tariffs: Winners and Losers
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Here’s Why Call Option Traders Love Dutch Bros Stock
Receive News & Ratings for Arch Biopartners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Biopartners and related companies with MarketBeat.com's FREE daily email newsletter.
